Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
124.40
19.26
−13.41%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) revenue by segment, product and region
Revenue by product or service $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Screening revenue | 139 94.18% | 109 86.49% | 75 80.55% | 40 71.68% |
| Development Services | 9 5.82% | 17 13.51% | 18 19.45% | 16 28.32% |
| Revenue | 147 | 126 | 93 | 56 |
Gross profit by product or service $m, and margin
Operating figures as reported in each quarter’s results release or filing
| Figure | Quarter | Latest | A year before | Change |
|---|---|---|---|---|
| Galleri test volume | Q3 FY2026 | 56.0K | — | — |